



## Advances in Vector-Based Immunization: Exploring the Next Horizon of Vaccine Technology

Guest Editor:

**Dr. Jingen Zhu**

Department of Biology, Catholic  
University of America,  
Washington, DC, USA

Deadline for manuscript  
submissions:

**31 July 2024**

### Message from the Guest Editor

Vector-based immunization offers numerous advantages, including the potential to stimulate broader and more robust immune responses, co-deliver multiple antigens from various pathogens, and rapidly adapt to new and evolving infectious agents. This platform is especially crucial when we consider pathogens with high mutation rates or those for which traditional vaccine approaches have been less successful.

In view of your deep expertise and commitment to this field, we invite you to contribute an original article, observation, report, or review in order to underscore the following aspects of this field:

- The development of vector vaccines against infectious diseases such as coronavirus, influenza virus, HIV, etc.
- Universal vaccines against pathogens with high mutation rates, such as SARS-CoV-2 and influenza viruses.
- The underlying mechanisms and biology of vector-based immunization.
- Recent successes and failures in the realm of vector-based vaccine candidates.
- Challenges and strategies in circumventing host-vector interactions that may diminish vaccine efficacy.
- The future trajectory of vector-based immunization in addressing global infectious threats.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)